ClinicalTrials.gg
CompletedNCT02442440ACIdoSISUpdated Sep 29, 2021

Anisodamine Critically Ill SeptIc Shock

A Phase 1/2 interventional study of anisodamine in Septic Shock, sponsored by Jinhua Central Hospital. Completed at 15 sites in China. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2021-09-29.

Sponsored by Jinhua Central Hospital · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
355
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 89 studies in Shock, Septic with a site in China — 30 open to participants now, 32 under way, 1 of them phase 3. Shock, Septic · China.

Enrollment
10th of 62
355 · median 72
Started
2015
with 3 others
Phase 1/2
4 of 89
none open now
Registered
19th of 89
by date
Lead sponsor
2 of 89
Jinhua Central Hospital

Among the 89 studies in Shock, Septic with a site in China, this one is the 10th largest by enrollment of the 62 interventional ones that give a count, is one of 4 that started in 2015, is one of 4 in phase 1/2, and was the 19th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

30 of the 89 studies in Shock, Septic with a site in China are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 89 studies in Shock, Septic with a site in China, or all of them as a file.
02

Study summary

Anisodamine has been widely used in China for its pharmacological effect on improving microcirculation during shock. It has been reported that anisodamine is effective in reducing mortality rate in children with meningitis. however, its effectiveness in patients with septic shock has not been systematically investigated. The aim of the study is to investigate the effectiveness of anisodamine in the treatment of patients with septic shock.

Read the detailed description

Septic shock is an important contributor of mortality in the intensive care unit (ICU). The crude mortality is reported to be from 30% to 65% (1-5). Although there are significant advances in the management of septic shock in recent decades, the mortality rate was only marginally reduced. For example, the CUB-Réa Network study reported that the mortality rate of septic shock declined from 62.1% in 1993 to 55.9% in 2000 (6). The well-known Surviving Sepsis Campaign has also made every effort to reduce mortality rate of severe sepsis and septic shock. The organization recommended bundled strategies including early goal directed therapy (EGDT) for the management of septic shock (7,8). Although EGDT was once the mainstay therapy of septic shock, its efficacy has been questioned by recent several large randomized controlled trials (9,10). Therefore, the treatment of septic shock is still a global challenge and there is no well-established intervention that can reduce its mortality.

Anisodamine is an active agent isolated from a Chinese herb medicine. Both experimental and clinical studies have shown some potential beneficial effects of anisodamine in improving outcomes of shock (11-13). It was reported that anisodamine could reduce the mortality rate of fulminant epidemic meningitis from 66.9% to 12.4% (14). The efficacy of anisodamine might be mediated via the inhibition of thromboxane synthesis, granulocyte and platelet aggregation (15). Although anisodamine has been widely used in the treatment of septic shock in mainland China, there is no solid evidence from well designed clinical trials to support its efficacy. The aim of the study is to investigate the effectiveness of anisodamine in the treatment of critically ill patients with septic shock.

03

Conditions studied

  • Septic Shock

Browse trials for

Keywords

  • anisodamine
  • septic shock
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • patients with septic shock

Inclusion criteria included patients with sepsis plus use of vasopressors. Systemic inflammatory response syndrome (SIRS) is defined as meeting at least one of the following 3 criteria for a systemic inflammatory response. One of the SIRS criteria must be either the WBC criteria (a) or the body temperature criteria (b):

  1. White blood cell count >12,000 or \<4,000 or >10% band forms
  2. Body temperature >38oC (any route) or \<36oC (accepting core temperatures only; indwelling catheter, esophageal, rectal)
  3. Heart rate (> 90 beats/min) or receiving medications that slow heart rate or paced rhythm.

Suspected or documented infection included the following sites: thorax, urinary tract, abdomen, skin, sinuses, central venous catheters, and bacterial meningitis.

Septic shock was defined as sustained arterial hypotension with systolic blood pressure (SBP) \< 90 mm Hg, mean arterial pressure (MAP) \< 70 mm Hg, or an SBP decrease > 40 mm Hg, despite adequate fluid resuscitation. To ease clinical screening process, we defined septic shock as the requirement of vasopressors despite adequate fluid resuscitation. Vasopressors include norepinephrine, epinephrine, phenylephrine and dopamine>5mcg/kg/min.

Patients with following conditions will be excluded:

  1. Age\<15 years old
  2. Moribund (expected to die within 24 hours)
  3. Stay in ICU for more than 24 hours
  4. to anisodamine: elevated intracranial pressure, acute phase of intracranial hemorrhage, glaucoma, untreated bowel obstruction (surgically treated obstruction is not contraindicated), enlargement of prostate without urinary catheterization.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
355 participants (actual)

Study arms

  • Experimental
    anisodamine group

    administration of the drug

    Drug: anisodamine

  • No intervention
    control group

    these arm do not use anisodamine, other resuscitation protocol is as usual.

Interventions

  • Anisodamine will be given first as bolus of 10 mg, followed by 0.1-0.5mg/kg/hr. The adjustment of pump infusion rate is largely at the discretion of treating physician, with the aim of improving microcirculation and limit the side effect to a minimum. For example, if serum lactate continues to elevate, the infusion rate can be increased. Discontinuation on severe side effect or recovery of shock (normalized lactate, weaned from vasopressor) or death.

    Also known as: 654-2

06

What researchers measure

Primary outcomes

  1. hospital mortality

    the outcome will be assessed by using proportion of patients died, and relative risk will be reported.

    Time frame: from ICU admission to hospital discharge (participants will be followed for the duration of hospital stay, an expected average of 28 days)

Secondary outcomes

  1. lactate levels

    the value was measured in mmol/l, and they will be compared between both arms.

    Time frame: from ICU admission to hospital discharge (participants will be followed for the duration of hospital stay, an expected average of 28 days)

07

Study locations

15 sites
  • Huizhou first hospital
    Huizhou, Guangdong 516000, China
  • Union Hospital, Tongji medical collegue, Huazhong university of Science and Technology
    Wuhan, Hubei, China
  • the First Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210029, China
  • affiliated hospital, Jiangsu University
    Zhenjiang, Jiangsu, China
  • Binzhou People's hospital of Shandong province
    Binzhou, Shandong, China
  • department of critical care medicine, Ren Ji Hospital, School of medicine, Shanghai Jiao Tong University
    Shanghai, Shanghai 200001, China
  • Peace hospital of Changzhi medical college
    Changzhi, Shanxi, China
  • Zhejiang Hospital
    Hangzhou, Zhejiang 310000, China
  • Sir Run Run Shaw hospital
    Hangzhou, Zhejiang 321000, China
  • Sir Run Run Shaw hospital
    Hangzhou, Zhejiang, China
  • Jinhua Municipal Central Hospital
    Jinhua, Zhejiang 321000, China
  • Department of critical care medicine, The central hospital of Lishui City
    Lishui, Zhejiang 323000, China
  • Beilun People's hospital; The first affiliated hospital of Zhejiang university (Beilun Branch)
    Ningbo, Zhejiang, China
  • Taizhou hospital of Zhejiang province
    Taizhou, Zhejiang 317000, China
  • The first People's hospital of Yongkang
    Yongkang, Zhejiang, China
08

References and documents

Publications

  • Yu Y, Zhu C, Hong Y, Chen L, Huang Z, Zhou J, Tian X, Liu D, Ren B, Zhang C, Hu C, Wang X, Yin R, Gao Y, Zhang Z. Effectiveness of anisodamine for the treatment of critically ill patients with septic shock: a multicentre randomized controlled trial. Crit Care. 2021 Sep 27;25(1):349. doi: 10.1186/s13054-021-03774-4. PubMed 34579741 ↗
  • Zheng Y, Li Y, Liu X, Zhang R, Wang Z, Sun H, Liu S. A phase III, multicenter randomized controlled trial of neo-adjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIA-IIIB esophageal squamous cell carcinoma. J Thorac Dis. 2017 Jan;9(1):200-204. doi: 10.21037/jtd.2017.01.44. PubMed 28203424 ↗
  • Zhang Z, Zhou J, Shang Y, Wang X, Yin R, Zhu Z, Chen W, Tian X, Yu Y, Zuo X, Chen K, Ji X, Ni H; Anisodamine Critically Ill SeptIc Shock (ACIdoSIS) study group. Effectiveness of anisodamine for the treatment of critically ill patients with septic shock (ACIdoSIS study): study protocol for randomized controlled trial. Ann Transl Med. 2015 Oct;3(17):246. doi: 10.3978/j.issn.2305-5839.2015.10.03. PubMed 26605292 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Oct 2020 and a completion of Oct 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2015
First posted
May 13, 2015
Start
Apr 2015
Primary completionActual
Oct 2020
CompletionActual
Oct 1, 2020
Last update
Sep 29, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02442440
Lead sponsor
Jinhua Central Hospital
Responsible party
Zhongheng Zhang (Dr., Jinhua Central Hospital) — Principal investigator
First posted
May 13, 2015
Start date
Apr 2015
Primary completion
Oct 2020
Completion
Oct 1, 2020
Last update
Sep 29, 2021

Study contacts

kun chen, MSc
study director · Jinhua Municipal Central Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anisodamine

Start the discussion